Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Molecular Partners AG - American Depositary Shares (NQ:MOLN)

4.456 +0.256 (+6.10%)
Streaming Delayed Price Updated: 2:22 PM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Molecular Partners AG - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Hold Three Poster Presentations at AACR 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac) 
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present at Upcoming Investor Conferences
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports Financial Results and Highlights from Q1 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to hold three poster presentations at AACR 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Publishes Invitation to Annual General Meeting 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
From Molecular Partners
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.